NurExone Biologic Inc. is a publicly-traded biopharma company, listed on the Toronto Stock Exchange (TSXV: NRX), the OTCQB Venture Market (OTCQB:NRXBF) and Frankfurt Stock Exchange (TSXV: NRX). NurExone is developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs.
NurExone Biologic is a trailblazer in HealthTech innovation, dedicated to transforming the treatment of central nervous system injuries. The company’s lead product, ExoPTEN, harnesses cutting-edge exosome-based and RNA technology to promote minimally-invasive nerve regeneration, reconnection, and meaningful functional recovery:
- ExoPTEN is the first known minimally invasive therapy that has successfully promoted nerve regeneration and functional recovery following complete spinal cord transection. Recovery of motor function, sensation, and bladder control was observed in 75%-100% of animals after a brief intranasal/intrathecal ExoPTEN treatment cycle
- Showed also functional restoration of damaged eyes to healthy levels in animals (Glaucoma model)
By leveraging the natural delivery capabilities of exosomes combined with precision RNA therapeutics, NurExone offers new hope for patients with neurological damage, setting a bold standard for science-driven healthcare solutions. 
